Pittsburgh Life Sciences Alliance

Pittsburgh is emerging as a powerhouse in life sciences innovation, driven by two key growth platforms - data-driven health and the discovery and manufacturing of next-generation precision medicine and therapeutics. But what makes the region uniquely positioned for success in this space? Join us for an engaging discussion with Megan Kahn Shaw, President & CEO of Pittsburgh Life Sciences Alliance (PLSA), as we explore: - The distinctive strengths and innovations coming out of Pittsburgh’s life sciences ecosystem. - Why data-driven health and next-gen precision medicine are driving global industry growth. - Standout Pittsburgh companies leading the charge in these high-impact areas. - The role of PLSA in advancing the region’s life sciences sector and its mission for long-term success. With deep expertise spanning investment, commercialization, and strategic growth, Megan brings a wealth of knowledge on what it takes to turn groundbreaking research into real-world impact. Don’t miss this opportunity to gain insights into Pittsburgh’s growing influence in life sciences and what it means for the future of healthcare innovation! ?????????? ?????????? ???????? Megan Shaw, President & CEO of Pittsburgh Life Sciences Alliance (PLSA)?is a mission-driven healthcare and life sciences leader with 20 years of experience in strategy development, early stage investing, and development of growth companies. Previously, as Managing Director of Life Sciences at Innovation Works, she managed investments in over 35 life science startups, launched AlphaLab Health seed-stage healthcare accelerator in partnership with Allegheny Health Network, and served as a board observer for numerous portfolio companies. Megan also served with NIH’s Rapid Acceleration of Diagnostics initiative to identify and scale up technologies to detect SARS-CoV-2 during the pandemic, including serving on the Variant Task Force. Earlier, she was employee #1 at HemoSonics, a company sprung from research at the University of Virginia that developed a novel point of care coagulation diagnostic. As vice president of marketing and business development, she established the business infrastructure and led the commercial leadership team in developing and launching an outcome-changing product. HemoSonics was acquired by French multinational Diagnostica Stago in a successful exit. Megan began her career as a strategy consultant for Monitor Group, a consultancy founded by Michael Porter, and previously worked at two mid-market private equity funds. Sponsored by CRB.

?? ?? Eric Topol: "Spatial biology is lighting it up" ?? ?? We had a fantastic opportunity to connect with Dr. Eric Topol in our latest #SpatialThreads episode and had a rich and scintillating discussion around #SpatialBiology and other topics.! ?? Dr. Topol shared his thoughts on why #SpatialBiology is lighting it up and how AI-powered insights are shaping the future of healthcare. ?? ?? ?? Watch the full interview on YouTube: https://lnkd.in/eeq2A7SS #SpatialMedicine #ExplainableAI #PrecisionOncology #FutureOfHealthcare #CancerTherapeutics #SpatialIntelligence #SpatialAnalytics #Innovation Dusty Majumdar, PhD S. Chakra Chennubhotla Craig Cinquina Akif Burak Tosun Filippo Pullara Brian Falkenstein Raymond Yan Niro Ramachandran , Nathan McDonald, Ajit Singh Ven Raju Gowri Shankar Harry Glorikian Lan Fong Arutha Kulasinghe Roma Batra, PhD, MBA Sunandini Chopra Sahirzeeshan (Sahir) Ali Sam Hanash Jeffrey Scott Vineeta Agarwala, MD PhD Laura Dillon Paul Schrimpf Tullia Bruno Sid Jain Jeff Cohen

Pittsburgh is emerging as a powerhouse in life sciences innovation, driven by two key growth platforms - data-driven health and the discovery and manufacturing of next-generation precision medicine and therapeutics. But what makes the region uniquely positioned for success in this space? Join us for an engaging discussion with Megan Kahn Shaw, President & CEO of Pittsburgh Life Sciences Alliance (PLSA), as we explore: - The distinctive strengths and innovations coming out of Pittsburgh’s life sciences ecosystem. - Why data-driven health and next-gen precision medicine are driving global industry growth. - Standout Pittsburgh companies leading the charge in these high-impact areas. - The role of PLSA in advancing the region’s life sciences sector and its mission for long-term success. With deep expertise spanning investment, commercialization, and strategic growth, Megan brings a wealth of knowledge on what it takes to turn groundbreaking research into real-world impact. Don’t miss this opportunity to gain insights into Pittsburgh’s growing influence in life sciences and what it means for the future of healthcare innovation! ?????????? ?????????? ???????? Megan Shaw, President & CEO of Pittsburgh Life Sciences Alliance (PLSA)?is a mission-driven healthcare and life sciences leader with 20 years of experience in strategy development, early stage investing, and development of growth companies. Previously, as Managing Director of Life Sciences at Innovation Works, she managed investments in over 35 life science startups, launched AlphaLab Health seed-stage healthcare accelerator in partnership with Allegheny Health Network, and served as a board observer for numerous portfolio companies. Megan also served with NIH’s Rapid Acceleration of Diagnostics initiative to identify and scale up technologies to detect SARS-CoV-2 during the pandemic, including serving on the Variant Task Force. Earlier, she was employee #1 at HemoSonics, a company sprung from research at the University of Virginia that developed a novel point of care coagulation diagnostic. As vice president of marketing and business development, she established the business infrastructure and led the commercial leadership team in developing and launching an outcome-changing product. HemoSonics was acquired by French multinational Diagnostica Stago in a successful exit. Megan began her career as a strategy consultant for Monitor Group, a consultancy founded by Michael Porter, and previously worked at two mid-market private equity funds. Sponsored by CRB.

?? ?????????? ??????????????????????????: New Abridge Contextual Reasoning Engine, $250M Series D, and 100+ enterprise customers. ?? Streamlined clinical and financial workflows, powered by the new Abridge Contextual Reasoning Engine ?? $250M Series D round, led by investors Elad Gil and IVP (click below for the full list of investors) ?? Privileged to serve 100+ of the largest health systems “We aspire to serve our health system partners for the decades to come. This investment supports that aspiration, as well as the core research and development that differentiates our approach.” —Dr. Shivdev Rao, CEO and Founder of Abridge Read more —> https://lnkd.in/e6h--aNP

This week, Council Leader Tom Hunt, and Chief Executive, Kate Josephs CB are visiting our Sister City, Pittsburgh. Day two of the trip has focused on health, wellbeing and innovation – areas both Sheffield and Pittsburgh share strengths in. They met with experts at UPMC, the University of Pittsburgh and the Pittsburgh Life Sciences Alliance to learn how the city is developing new healthcare technologies and attracting investment to scale up innovative new healthcare companies. The team also toured Holtec International’s manufacturing facility in Pittsburgh. Holtec have recently selected South Yorkshire as the preferred site for its new small modular reactor factory. Find out more about the visit here: https://lnkd.in/eDE_xeZF